KOPRAN
|
The Current P/E Ratio of KOPRAN is 38.71.
| Share Price | ₹200.2 | Aug 20,2026 |
| Market Cap | ₹967.0 Cr | |
| Earnings-TTM | ₹25.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 38.71x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of KOPRAN
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹967.0 Cr] as on Aug 20,2026
(/) Earnings [ ₹25.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 38.71x ]
Thus, for KOPRAN , the investors are currently willing to pay 38.71 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of KOPRAN !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of KOPRAN over the last five years.
Historical PE (Price/Earnings) ratio chart of KOPRAN
PE Ratio Performance Analysis for KOPRAN
- KOPRAN 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 21.68x.
- KOPRAN 's operated at median p/e ratio of 21.93x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, KOPRAN 's p/e ratio peaked in Mar2024 at 24.45x.
- KOPRAN 's p/e ratio hit its five-year low in Mar2023 of 19.55x.
How does KOPRAN 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| KOPRAN | 24.98 | 38.71 | 967.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.47 | 456,114.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 77.93 | 227,958.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 88.12 | 189,990.0 |
| CIPLA LTD | 3,364.84 | 34.52 | 116,141.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.11 | 98,604.4 |
| MANKIND PHARMA LTD | 2,055.11 | 47.93 | 98,499.5 |
| LUPIN LTD | 5,551.01 | 18.15 | 100,733.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.62 | 110,603.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 24.90 | 92,428.7 |
| LAURUS LABS LTD | 1,090.76 | 90.30 | 98,498.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs KOPRAN 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.15x |
| Max industry PE | 90.30x |
| Median industry PE | 37.47x |
| Average industry PE | 46.71x |
You may also like the below Video Courses